机器人辅助腹腔镜根治性肾切除术中cT1 - cT2肾癌患者同时行肾上腺切除术的肿瘤相关危险因素

Q1 Medicine
J. Daza, A. Beksac, M. Kannappan, Julio T Chong, R. Abaza, A. Hemal, J. Sfakianos, K. Badani
{"title":"机器人辅助腹腔镜根治性肾切除术中cT1 - cT2肾癌患者同时行肾上腺切除术的肿瘤相关危险因素","authors":"J. Daza, A. Beksac, M. Kannappan, Julio T Chong, R. Abaza, A. Hemal, J. Sfakianos, K. Badani","doi":"10.23736/S0393-2249.19.03440-4","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nIn some cases, preservation of adrenal gland could be at risk in patients with cT1 and cT2 RCC. The aim of this study is to evaluate tumor-related factors that can potentially increase the risk of simultaneous adrenalectomy during robotic-assisted laparoscopic radical nephrectomy (RALRN) in patients with cT1 - cT2 disease and the impact of performing such procedure on recurrence-free survival (RFS) and complication rates.\n\n\nMETHODS\nWe used a multi-institutional kidney cancer database where we identified patients who underwent RALRN with or without adrenalectomy. We evaluated the tumor-related characteristics that could potentially increase the risk of adrenal gland resection of these patients. We also reported RFS at 12 - 24 months of follow-up, which was compared with an inverse probability of treatment weighted (IPTW) multivariable cox proportional hazards regression model and post-operative complications, which was compared with an IPTW multivariable logistic regression model.\n\n\nRESULTS\nTumor size, cT stage, pT stage, histologic subtype, sarcomatoid differentiation, BMI, lymph node involvement, metastatic disease, Fuhrman grade do not increase the risk of simultaneous adrenalectomy during RALRN. Moreover, RALRN with adrenalectomy had no significant benefit in RFS. No differences in post-operative complications were noted.\n\n\nCONCLUSIONS\nOur evaluated tumor-related characteristics did not show to impact the incidence of simultaneous adrenalectomy. Adrenal gland resection T does not provide significant benefit in recurrence-free survival. We consider that RALRN with adrenalectomy should be reserved only for patients with adrenal compromise as stated previously regardless that it has shown to be a safe procedure.","PeriodicalId":49015,"journal":{"name":"Minerva Urologica E Nefrologica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Identifying tumor-related risk factors for simultaneous adrenalectomy in patients with cT1 - cT2 kidney cancer during robotic assisted laparoscopic radical nephrectomy.\",\"authors\":\"J. Daza, A. Beksac, M. Kannappan, Julio T Chong, R. Abaza, A. Hemal, J. Sfakianos, K. Badani\",\"doi\":\"10.23736/S0393-2249.19.03440-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND\\nIn some cases, preservation of adrenal gland could be at risk in patients with cT1 and cT2 RCC. The aim of this study is to evaluate tumor-related factors that can potentially increase the risk of simultaneous adrenalectomy during robotic-assisted laparoscopic radical nephrectomy (RALRN) in patients with cT1 - cT2 disease and the impact of performing such procedure on recurrence-free survival (RFS) and complication rates.\\n\\n\\nMETHODS\\nWe used a multi-institutional kidney cancer database where we identified patients who underwent RALRN with or without adrenalectomy. We evaluated the tumor-related characteristics that could potentially increase the risk of adrenal gland resection of these patients. We also reported RFS at 12 - 24 months of follow-up, which was compared with an inverse probability of treatment weighted (IPTW) multivariable cox proportional hazards regression model and post-operative complications, which was compared with an IPTW multivariable logistic regression model.\\n\\n\\nRESULTS\\nTumor size, cT stage, pT stage, histologic subtype, sarcomatoid differentiation, BMI, lymph node involvement, metastatic disease, Fuhrman grade do not increase the risk of simultaneous adrenalectomy during RALRN. Moreover, RALRN with adrenalectomy had no significant benefit in RFS. No differences in post-operative complications were noted.\\n\\n\\nCONCLUSIONS\\nOur evaluated tumor-related characteristics did not show to impact the incidence of simultaneous adrenalectomy. Adrenal gland resection T does not provide significant benefit in recurrence-free survival. We consider that RALRN with adrenalectomy should be reserved only for patients with adrenal compromise as stated previously regardless that it has shown to be a safe procedure.\",\"PeriodicalId\":49015,\"journal\":{\"name\":\"Minerva Urologica E Nefrologica\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Minerva Urologica E Nefrologica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.23736/S0393-2249.19.03440-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva Urologica E Nefrologica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S0393-2249.19.03440-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3

摘要

背景:在某些情况下,cT1和cT2肾细胞癌患者保留肾上腺可能存在风险。本研究的目的是评估cT1 - cT2疾病患者在机器人辅助腹腔镜根治性肾切除术(RALRN)中可能增加同时肾上腺切除术风险的肿瘤相关因素,以及实施此类手术对无复发生存期(RFS)和并发症发生率的影响。方法:我们使用了一个多机构肾癌数据库,在那里我们确定了接受RALRN合并或不合并肾上腺切除术的患者。我们评估了可能增加这些患者肾上腺切除术风险的肿瘤相关特征。我们还报道了随访12 - 24个月的RFS,并将其与治疗加权逆概率(IPTW)多变量cox比例风险回归模型和术后并发症进行比较,并将其与IPTW多变量logistic回归模型进行比较。结果肿瘤大小、cT分期、pT分期、组织学亚型、肉瘤样分化、BMI、淋巴结累及、转移性、Fuhrman分级均不增加RALRN中同时行肾上腺切除术的风险。此外,RALRN与肾上腺切除术在RFS中没有显著的益处。术后并发症无明显差异。结论我们评估的肿瘤相关特征不影响同期肾上腺切除术的发生率。肾上腺切除术对无复发生存期没有显著的益处。我们认为RALRN与肾上腺切除术应该只保留给患者肾上腺损害,如前所述,无论它已被证明是一个安全的程序。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Identifying tumor-related risk factors for simultaneous adrenalectomy in patients with cT1 - cT2 kidney cancer during robotic assisted laparoscopic radical nephrectomy.
BACKGROUND In some cases, preservation of adrenal gland could be at risk in patients with cT1 and cT2 RCC. The aim of this study is to evaluate tumor-related factors that can potentially increase the risk of simultaneous adrenalectomy during robotic-assisted laparoscopic radical nephrectomy (RALRN) in patients with cT1 - cT2 disease and the impact of performing such procedure on recurrence-free survival (RFS) and complication rates. METHODS We used a multi-institutional kidney cancer database where we identified patients who underwent RALRN with or without adrenalectomy. We evaluated the tumor-related characteristics that could potentially increase the risk of adrenal gland resection of these patients. We also reported RFS at 12 - 24 months of follow-up, which was compared with an inverse probability of treatment weighted (IPTW) multivariable cox proportional hazards regression model and post-operative complications, which was compared with an IPTW multivariable logistic regression model. RESULTS Tumor size, cT stage, pT stage, histologic subtype, sarcomatoid differentiation, BMI, lymph node involvement, metastatic disease, Fuhrman grade do not increase the risk of simultaneous adrenalectomy during RALRN. Moreover, RALRN with adrenalectomy had no significant benefit in RFS. No differences in post-operative complications were noted. CONCLUSIONS Our evaluated tumor-related characteristics did not show to impact the incidence of simultaneous adrenalectomy. Adrenal gland resection T does not provide significant benefit in recurrence-free survival. We consider that RALRN with adrenalectomy should be reserved only for patients with adrenal compromise as stated previously regardless that it has shown to be a safe procedure.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Minerva Urologica E Nefrologica
Minerva Urologica E Nefrologica UROLOGY & NEPHROLOGY-
CiteScore
5.50
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: The journal Minerva Urologica e Nefrologica publishes scientific papers on nephrology and urology. Manuscripts may be submitted in the form of Minerva opinion editorials, editorial comments, original articles, video illustrated articles, review articles and letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信